Satsuma Pharmaceuticals, Inc. 4 SEC Filings

Filed On	Filing
12 Jun 2023	Form 4: Ra Capital MANAGEMENT, L.p., Former 10% Owner and 2 others Disposed of 5,914,252 shares (Tender Offer) · Disposed of 60,000 Stock Option (Right to Buy) (Disposition to Issuer)
08 Jun 2023	Form 4: Riebe Michael T, Director Disposed of 100,423 Stock Option (right to buy) (Disposition to Issuer)
08 Jun 2023	Form 4: Takanashi Ken, Director Bought 22,053,581 shares ($20.1M) · Disposed of 60,000 Stock Option (right to buy) (Disposition to Issuer)
08 Jun 2023	Form 4: Shah Rajeev M., Director Disposed of 5,914,252 shares (Tender Offer) ($5.38M) · Disposed of 60,000 Stock Option (right to buy) (Disposition to Issuer)
08 Jun 2023	Form 4: O'Neil Thomas P., Chief Financial Officer Disposed of 13,877 shares (Tender Offer) ($12.6K) · Disposed of 478,935 Stock Option (right to buy) (Disposition to Issuer)
08 Jun 2023	Form 4: Sandoval Elisabeth, Director Disposed of 74,893 Stock Option (right to buy) (Disposition to Issuer)
08 Jun 2023	Form 4: Soloway Thomas P, Director Disposed of 70,000 Stock Option (right to buy) (Disposition to Issuer)
08 Jun 2023	Form 4: Shin Nippon Biomedical Laboratories, Ltd., 10% owner Bought 22,053,581 shares ($20.1M) · Bought 8,423,732 shares ($7.67M)
08 Jun 2023	Form 4: King Thomas Braxton, Director Disposed of 100,423 Stock Option (right to buy) (Disposition to Issuer)
08 Jun 2023	Form 4: Lukatch Heath, Director Disposed of 70,000 Stock Option (right to buy) (Disposition to Issuer)
08 Jun 2023	Form 4: Kollins John A, Director Disposed of 305,911 shares (Tender Offer) ($278K) · Disposed of 1,579,572 Stock Option (right to buy) (Disposition to Issuer)
08 Jun 2023	Form 4: Harsch Mutya, Director Disposed of 70,000 Stock Option (right to buy) (Disposition to Issuer)
23 Nov 2022	Form 4: Leonard Braden Michael, 10% owner Bought 150,000 shares ($107K)
16 Nov 2022	Form 4: Leonard Braden Michael, 10% owner Bought 5,608,306 shares ($3.87M) · Bought 831,694 shares ($526K)
16 Nov 2022	Form 4: Commodore Capital Lp, 10% owner Sold 3,250,000 shares ($2.29M)
07 Jun 2022	Form 4: O'Neil Thomas P., Chief Financial Officer Granted 190,000 Stock Option (Right to Buy)
07 Jun 2022	Form 4: Albrecht Detlef, Chief Medical Officer Granted 190,000 Stock Option (Right to Buy)
07 Jun 2022	Form 4: Kollins John A, Director Granted 505,000 Stock Option (Right to Buy)
07 Jun 2022	Form 4: Lukatch Heath, Director Granted 30,000 Stock Option (Right to Buy)
07 Jun 2022	Form 4: Sandoval Elisabeth, Director Granted 30,000 Stock Option (Right to Buy)

Comments